Who Paid My Doc
Charles Millhuff
Child & Adolescent Psychiatry Topeka, KS Doctor of Osteopathy
NPI 1114080785 CMS profile 1135300
325 Sw Frazier Ave, Topeka, KS 66606
General payments
$139
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$9,640
Through program year 2025, Charles Millhuff of Topeka, KS is reported in the CMS Open Payments database as having received $139 across 7 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,640 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 42nd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $24 | 1 | |
| 2022 | General | $12 | 1 | |
| 2021 | General | $3 | 1 | |
| 2020 | General | $34 | 2 | |
| 2019 | General | $66 | 2 |
Beside peers
- Charles Millhuff
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Charles Millhuff were reported at $24. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Charles Millhuff | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $66 | $129 | $42–$419 | $163 |
| 2020 | $34 | $81 | $28–$226 | $114 |
| 2021 | $3 | $115 | $31–$326 | $132 |
| 2022 | $12 | $124 | $40–$382 | $149 |
| 2023 | $0 | $130 | $45–$420 | $160 |
| 2024 | $0 | $141 | $42–$490 | $164 |
| 2025 | $24 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
34
Drug cost
$504
Branded share of claims
67.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Guanfacine Hcl Er Guanfacine Hcl | Brand | 23 | $471 | |
| Fluoxetine Hcl | Generic | 11 | $34 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in Kansas
Tahira Masood
Child & Adolescent Psychiatry · Overland Park, KS
William Warnes
Child & Adolescent Psychiatry · Leavenworth, KS
Jaclyn Legg
Child & Adolescent Psychiatry · Prairie Village, KS
Raju Kakarlapudi
Child & Adolescent Psychiatry · Overland Park, KS
Jyotsna Adma
Child & Adolescent Psychiatry · Kansas City, KS
Stephanie Brooks
Child & Adolescent Psychiatry · Fort Leavenworth, KS
Related records
Child & Adolescent Psychiatry in Kansas
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Kansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.